6:00 PM – 7:00 PM Reception; 7:00 PM – 8:00 PM Lecture and Q&A
The New York Academy of Medicine, 1216 Fifth Avenue at 103rd Street, New York, NY 10029
Free, but advance registration is required
This lecture will relate the voyage of discovery from studies in an animal model of membranous nephropathy to the identification of the phospholipase A2 receptor (PLA2R) as the target of autoantibodies in the human disease. It will touch on points along the journey where serendipity shone her light on the way forward.
About the Lecturer
David J. Salant, MD, BCh, is the Norman G. Levinsky Professor, Chief of Nephrology and Vice-Chair for Research in the Department of Medicine at Boston University Medical Center. He graduated from the Witwatersrand University Medical School in 1969 and completed clinical training at the Johannesburg General Hospital. He received research training at Boston University with Dr. William Couser and joined the faculty in 1979. He was appointed Chief of Nephrology and Director of the Nephrology Training Program in 1987.
Supported by grants from the National Institutes of Health he has conducted extensive research on immune disorders of the kidneys, and Dr. Salant has authored over 180 scientific publications, reviews and book chapters. His work has focused on mechanisms of immune deposition and the role of complement in glomerular diseases, and on the structural biology of the podocyte. He was one of the earliest proponents of the notion that podocyte injury forms the basis of most, if not all, proteinuric kidney diseases. In a landmark New England Journal of Medicine paper in 2009, he and his colleagues described their discovery that a high proportion of patients with idiopathic membranous nephropathy have circulating autoantibodies to the M-type phospholipase A2 receptor on human podocytes.
Dr. Salant has received several awards and honors, including an Established Investigator Award from the American Heart Association, the Jean Hamburger Award from the International Society of Nephrology, the John P. Peters Award from the American Society of Nephrology, the Donald W. Seldin Award from the National Kidney Foundation, the Marilyn Farquhar Award at the 11th Annual Podocyte Conference and he was elected as a Fellow of the American Association for the Advancement of Science. He has served on several NIH advisory panels and on the editorial boards of several major journals. He has also played a prominent educational role nationally as member and chair of the American Board of Internal Medicine in Nephrology.